Immuneering Corp. (IMRX), a clinical-stage oncology enterprise, revealed optimistic preliminary results from the current Phase 1 part of its clinical trial of IMM-1-104 in advanced RAS-mutant solid tumors, on Thursday.
Prior to market opening on the Nasdaq, Immuneering's shares rose around 5.1 percent to $6.18.
As of February 20, Phase 1 patients exhibited a variety of twelve RAS mutations across eight different cancer types. IMM-1-104 displayed positive early indications of clinical activity and was well-received, presenting promising prospects for the Phase 2a segment of the study, according to the company.
"We are confident these findings provide substantial evidence of concept. IMM-1-104 demonstrated its potential by shrinking MAPK-dependent lesions in extremely aggressive, end-stage cancers, preventing RAS alterations, and comported well, indicating the potential for a unique safety profile," stated Ben Zeskind, Immuneering's CEO.
The Phase 1 section aimed to gauge IMM-1-104's safety and tolerability, identify a suitable recommendation for Phase 2 dose (RP2D), and assess pharmacokinetics or PK.
As of February 20, IMM-1-104 was well-tolerated, suggesting a unique safety profile. Among treatment-related adverse events (TRAEs) experienced by over 10% of patients, no grade 4 TRAEs were detected, only a single grade 3 TRAE was noted, and a limited number of grade 2 TRAEs were witnessed in each category.
No TRAEs were considered critical.
Although clinical activity was not an endpoint of the Phase 1 trial segment, Immuneering extrapolates from the data generated until February 20, 2024, that IMM-1-104 may reveal promising clinical activity.
The Phase 2a segment is examining IMM-1-104 as a single agent and in combined use, and it is hoped will offer the strongest evidence yet that IMM-1-104 has potential as an effective universal treatment for RAS-mutant solid tumors.
Immuneering intends to present further data from the ongoing Phase 1 part of its Phase 1/2a study of IMM-1-104 in advanced RAS-mutant solid tumors at an upcoming medical conference.
The company anticipates reporting initial data from multiple Phase 2a section arms in 2024 and plans to share that information later this year. For additional health news, visit rttnews.com.
